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Introduction:Hypoparathyroidism in pregnancy is rare, but important, as it is associatedwithmaternalmorbidity
and foetal loss. There are limited case reports and no establishedmanagement guidelines. Optimal maintenance
of calcium levels during pregnancy is required to minimise the risk of related complications. This study aims to
identify causes and examine outcomes of hypoparathyroidism in pregnancy in a cohort of women delivering
at a large referral centre.
Design andmethod: TheMonashHealthmaternity service database captures pregnancy and birthing outcomes in
over 9000 women each year. We audited this database between 2000 and 2014 to examine the clinical course,
treatment and outcomes of pregnant women with hypoparathyroidism.
Results: We identiﬁed 10 pregnancies from 6 women with pre-existing hypoparathyroidism secondary to
idiopathic hypoparathyroidism (n= 3), autosomal dominant branchial arch disorder with hypoparathyroidism
(n= 3) and autosomal dominant hypocalcaemia (n= 1), surgery for thyroid cancer (n=2) and Graves' disease
(n = 1). Maternal calcium levels were monitored through pregnancy and management adjusted to maintain
normocalcaemia. One woman was delivered by caesarean section at 34 weeks' gestation because of intrauterine
growth restriction, and oligohydramnios complicated two other pregnancies. The postpartum period was
complicated by severe hypercalcaemia in one woman and by symptomatic, labile serum calcium levels during
lactation in another woman, requiring close monitoring over a 6 month period.
Conclusion: Although rare, hypoparathyroidism in pregnancy poses a management challenge for clinicians, and
co-ordinated care is required by obstetricians and endocrinologists to ensure optimal outcomes for both mother
and baby. Continuedmonitoring ofmaternal calcium levels during lactation andweaning is essential to avoid the
potential complications of either hypercalcaemia or hypocalcaemia.
Crown Copyright © 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypoparathyroidism is rarely encountered during pregnancy but is
important, however, as it is associatedwithmaternalmorbidity and foe-
tal loss. There are limited case reports and no established management
guidelines. Physiological adaptations to maternal calcium metabolism
occur during pregnancy and lactation to facilitate mineralisation of the
foetal skeleton and ensure adequate calcium in breast milk, whilst
maintaining normal ionised and albumin-corrected serum calcium
levels (Kovacs, 2011). The challenge of managing hypoparathyroidism
in pregnancy is to maintain normocalcaemia in the setting of variable
individual responses to calcitriol and calcium supplementation, as well
as altered calcium homeostasis.l Research, Australia.
r Inc. This is an open access article unInadequate management of hypoparathyroidism during pregnancy
can result in miscarriage (Eastell et al., 1985), stillbirth (Callies et al.,
1998), preterm labour, and acute neonatalmorbidity such as respiratory
distress syndrome (Kaneko et al., 1999). Maternal hypocalcaemia can
also be complicated by neonatal secondary hyperparathyroidism
which in turn causes skeletal demineralization, subperiosteal bone
resorption and osteitis ﬁbrosa cystica. Conversely, overtreatment with
calcitriol causes maternal hypercalcaemia and suppression of the foetal
and neonatal parathyroid glands, and there is the additional concern of
teratogenicity using older vitamin D preparations (Roth, 2011).
Studies examining the management of hypoparathyroidism in
pregnancy and lactation are few, with the majority of data stemming
from single case reports. Only two case reports have been published
since 2000 (Krysiak et al., 2011; Sweeney et al., 2010). The largest
case series, published in 1998, described twelve women with maternal
hypoparathyroidism (Callies et al., 1998). Reports thus far have
demonstrated that whilst some women have reduced symptoms andder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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require increased doses. However, the physiological decline in serum
calcium due to haemodilution in pregnancy has sometimes been
misinterpreted as worsening hypocalcaemia resulting in the treatment
of women based on their laboratory results rather than clinical
symptoms (Kovacs, 2011; Eastell et al., 1985; Krysiak et al., 2011;
Markestad et al., 1983; Caplan and Beguin, 1990; Rude et al., 1984;
Mather et al., 1999; Sadeghi-Nejad et al., 1980; Wright et al., 1969).
There is consistent evidence that calcitriol requirements decrease
during lactation.
Monash Health's maternity service is the largest maternity provider
in Victoria, Australia, with an associated database that captures birthing
outcomes in over 9000 women each year. In this retrospective audit,
we outline the available cases and present the results of an audit of
the birthing outcomes database, examining ten pregnancies with pre-
existing maternal hypoparathyroidism over a ﬁfteen year period.
2. Subjects and methods
Ethics approval was obtained from the Monash Health Human
Research Ethics Committee to review the Birthing Outcomes System
database and identify all pregnancies presenting to the Obstetrics
Department between 2000 and 2014 with the concurrent diagnosis of
hypoparathyroidism. The diagnosis of hypoparathyroidism was
conﬁrmed with the biochemical ﬁndings of hypocalcemia and a low
serum parathyroid hormone (PTH) level. Subsequent review ofmedical
and biochemical records was performed to record clinical course, treat-
ment, and maternal and foetal outcomes of these pregnancies.
3. Results
The Birthing Outcomes System database identiﬁed twelve pregnan-
cies with pregnancy-associated hypoparathyroidism. Twowere excluded
due to lack of available data. The remaining ten pregnancies from six
women with a diagnosis of hypoparathyroidism will be described.
3.1. Cases
3.1.1. Pregnancy 1
A 37 year old woman attended pre-pregnancy counselling for
idiopathic hypoparathyroidism diagnosed two years earlier, following
episodic muscle twitching after the birth of her ﬁrst child. She denied
a family history of calcium disorders and had no clinically or biochemi-
cal evidence of other associated endocrinopathies.
The patient was managed with calcitriol 0.50 mcg twice daily and
calcium carbonate 600 mg twice daily, with a corrected serum calcium
of 2.13 mmol/L (normal 2.15–2.65 mmol/L). Once pregnancy was
conﬁrmed, her corrected calcium levels were monitored every
3 weeks with the aim of maintaining her corrected serum calcium at
the lower end of the normal range. Calcitriol requirements increased
during the second trimester and early third trimester to a maximum
dose of 1.00 mcg mane and 0.75 mcg nocte required to maintain
normocalcaemia. Serum calcium levels were maintained between 2.13
mmol/L and 2.38 mmol/L during pregnancy. Calcitriol doses were able
to be reduced in the latter part of the third trimester to 0.75 mcg
twice daily.
Following an uncomplicated pregnancy, the patient had a normal la-
bour and delivery of a healthy female baby weighing 3660 g at term
(75th percentile for gestation and sex (Dobbins et al., 2013)). Calcitriol
supplementation was decreased to pre-pregnancy levels of calcitriol
0.50 mcg twice daily by day 3 post-partum. The baby had normal
serum calciumwhen measured within a week of birth and at 4 months
of age. Breast-feeding was continued for 6 months. During lactation,
maternal serum calcium levels were maintained at 2.10 to 2.30 mmol/L
with no complications.3.1.2. Pregnancy 2 and 3
A 34 year old womanwith idiopathic hypoparathyroidism, seroneg-
ative arthritis and congenital limb hypoplasia presented in the ﬁrst
trimester of her second pregnancy for monitoring of her calcium levels.
Her initial management during pregnancy consisted of caltrate
2400 mg and calcitriol 0.75 mcg daily. To maintain normocalcaemia,
this was adjusted to caltrate 600 mg and calcitriol 1.00 mcg daily in
the third trimester. Her serum calcium levels weremaintained between
2.17 mmol/L and 2.46mmol/L during pregnancy with no noted compli-
cations. At 41+6 weeks' gestation she had induced onset of labour and
assisted vaginal birth of a healthy baby boy weighing 3435 g (50th
percentile for gestation and sex (Dobbins et al., 2013)).
During her ﬁrst pregnancy two years earlier, her serum calcium
levels had been maintained around 2.15 mmol/L with a peak serum
calcium level of 2.67 mmol/L in the second trimester. This necessitated
a decrease of her medications from calcitriol 0.75 mcg and caltrate
1800mg daily to calcitriol 0.50mcg and caltrate 1200mg daily. The preg-
nancy was complicated by vasa praevia and when born at 38+1 weeks'
gestation by elective caesarean, the baby developed transient tachypnoea
of the newborn, which resolved without therapy. Medication dose was
appropriately decreased postpartum to maintain eucalcaemia.
3.1.3. Pregnancy 4, 5 and 6
A23 year oldwomanwith a history of autosomal dominant branchial
arch disorder with hypoparathyroidism presented for review in the 13th
week of her ﬁfth pregnancy. Her hypoparathyroidism was diagnosed
when she presented with neonatal seizures andwas noted to have facial
weakness, malformed external ears, pre-auricular pits and deafness. Her
renal function was normal. Her father was similarly affected. She had
previously had two early pregnancy miscarriages and two pregnancies
complicated by symptomatic hypocalcemia, though these deliveries
were normal.
Thepatient presented in the13thweekof herﬁfth pregnancywithpe-
ripheral cramping and peri-oral tingling, however, her corrected serum
calcium was normal at 2.20 mmol/L. Initial doses of calcitriol 0.25 mcg
daily and calcium carbonate 1500 mg daily were titrated to calcitriol
0.50 mcg twice daily and caltrate 1200 mg twice daily by 15 weeks' ges-
tation. Though a documented calcium level of 2.09 mmol/L was noted 18
weeks' gestation, a corrected calcium level of 2.94mmol/L wasmeasured
a week later. Following titration of her calcitriol dose, normocalcaemia
was maintained for the remainder of the pregnancy with no noted com-
plications. She had a normal labour and vaginal delivery at term. The
baby was small for gestational age (SGA) with birth weight of 2440 g,
b3rd percentile for gestation and sex (Dobbins et al., 2013). Of note, ama-
ternal corrected calcium level of 2.87 mmol/L was noted post-delivery,
with titration of doses and normalisation of maternal serum calcium
levels by 1 week postpartum.
Fluctuating calcium levels were reported by the patient following
breastfeeding her child and she had three hospital admissions with
hypocalcaemic crises requiring IV calcium.
3.1.4. Pregnancy 7
A 38 year old womanwith autosomal dominant hypocalcaemia pre-
sented in the second trimester of her sixth pregnancy for review of cal-
cium levels. Shehad a past history of threemiscarriages and twohealthy
pregnancies and children with no reported antenatal complications.
Throughout the pregnancy, her calcium levels were maintained with
calcitriol 1.50 mcg daily and calcium carbonate. A maximum corrected
calcium level of 2.41 mmol/L was noted in week 28 with a minimum
corrected calcium level of 1.98 mmol/L in week 36, with no noted com-
plications throughout the pregnancy. At 39weeks' gestation, she had an
elective caesarean on a background of previous caesarean delivery, and
a healthy boy was born weighing 2840 g (10th percentile for gestation
and sex (Dobbins et al., 2013)). In the ﬁrst 3 weeks postpartum, the
mother developed hypercalcaemia up to 3.01 mmol/L and her calcitriol
dose was reduced to 1.00 mcg daily.
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A 28 year old woman presented one week post-partum with
vomiting, dizziness andmalaise. Hermedical history included hypopara-
thyroidism following thyroidectomy for papillary thyroid carcinoma in
2008. She was initially managed with thyroxine 100 μg daily, calcitriol
0.50mcg twice daily and calcium carbonate 1200mg twice daily. During
pregnancy, she was reviewed with titration of thyroxine doses up to
100 μg daily and 200 μg daily on alternate days, calcitriol 0.50 mcg
three times daily and calcium carbonate 1200 mg three times daily to
maintain eucalcaemia and thyroid function tests within trimester-
appropriate reference ranges. The birth was uncomplicated and she
had a normal vaginal birth of a healthy infant weighing 3620 g (90th
percentile for gestation and sex (Dobbins et al., 2013)) at term.
On presentation 1 week postpartum, the patient was vomiting and
was volume deplete. She had a serum calcium of 4.16 mmol/L (normal
2.15–2.65 mmol/L), with an ionised calcium of 2.04 mmol/L (normal
1.14–1.29 mmol/L). Renal function was normal but her serum phos-
phate was mildly elevated at 1.53 mmol/L, PTH was undetectable, and
her 25(OH) vitamin D was normal at 75 nmol/L. Her dose of calcitriol
and calcium carbonate had not been reduced following delivery and
she had been maintained on calcitriol 0.50 mcg three times daily and
calcium carbonate 1200mg three times daily for oneweek postpartum.
The patient was breast-feeding. Shewas admitted for ﬂuid replacement
and cardiac monitoring. Calcitriol and calcium carbonate were ceased
for oneweek, during which time serum calcium levels were monitored.
A serum calcium normalised after nine days.
In her ﬁrst pregnancy, corrected calcium levels within the normal
range had been maintained throughout pregnancy, reachingmaximum
of 2.39 mmol/L in week 9. This pregnancy was complicated by preterm
labour at 36 weeks' gestation with intrapartum bleeding and an abnor-
mal foetal heart rate on cardiotocogram. A healthy infant weighing
2820 g (50th percentile for gestation and sex (Dobbins et al., 2013))
was born. No issues of hypercalcaemia were noted post-partum.
3.1.6. Pregnancy 10
A 34 year old woman presented in her third pregnancywith a known
diagnosis of hypoparathyroidism secondary to thyroidectomy for Graves'
disease. She had an obstetric history of intrauterine growth restriction
(IUGR), preterm delivery, oligohydramnios, and caesarean birth. During
the ﬁrst trimester she was treated with caltrate 600 mg and calcitriol
0.75 mcg daily. This was titrated down to calcitriol 0.25 mcg daily in the
third trimester. Maximum corrected calcium reading was 2.46 mmol/L
in week 28. The antenatal period was complicated by oligohydramnios,
maternal hypertension, and suspected IUGR. A severely growth restricted
female baby weighing 1355 g (b1st percentile for gestation and sex
(Dobbins et al., 2013)) was born at 34+6 weeks' gestation by elective
caesarean. She required management of jaundice, SGA, and suspected
sepsis. Mild maternal hypocalcaemia (2.04 mmol/L) was incidentally
noted on biochemistry on a post-partum review.Table 1
Summary of case ﬁndings.






1(A) Idiopathic 2.13(1)–2.38(3) 1.00–1.75 37.1
2(B) Idiopathic 2.17(3)–2.46(2) 0.75–1.00 41.6
3(B) Idiopathic 2.15(3)–2.67(2) 0.50–0.75 38.1
4(C) Branchial arch disorder 1.97(3)–2.30(3) 0.75 38
5(C) Branchial arch disorder 1.77(1)–2.09(3) 1.50 39
6(C) Branchial arch disorder 2.09(2)–2.94(2) 0.25–1.00 39.4
7(D) Congenital 1.98(3)–2.41(3) 1.00–1.50 39
8(E) Secondary 2.38(1)–2.39(3) N/A 36
9(E) Secondary 2.25(1)–2.56(1) 1.00–1.50 40.1
10(F) Secondary 2.04(pp)–2.46(3) 0.25–0.75 34.6
Ten deliveries from 6women (A, B, C, D, E, F)were identiﬁed and the aetiology, corrected calciu
range for cCalcium= 2.15–2.65 mmol/L; Preterm delivery = delivery prior to 37 weeks gesta3.2. Review of cases
Twoof thewomen in this series had hypoparathyroidism as a result of
thyroidectomy performed prior to becoming pregnant; one for treatment
of Graves' disease (pregnancy 8, 9) and the other for papillary thyroid
cancer (pregnancy 10). Two women were diagnosed with idiopathic
hypoparathyroidism at the age of 33 (pregnancy 1) and 23 (pregnancy
2, 3). Congenital hypoparathyroidism accounted for the remaining
two women. One was diagnosed with a branchial arch anomaly with
hypoparathyroidism at 3 weeks of age (pregnancy 4, 5, 6), and the
other diagnosed with autosomal dominant hypocalcaemia at the age
of 27 (pregnancy 7).
Of note, 2/6 women had a history of multiple miscarriages. These
womenwere known to have labile serum calcium levels during pregnan-
cy (see Table 1). IUGR was suspected in 2/10 pregnancies (pregnancy 6
and 10) and 3/10 newborns were SGA (pregnancy 6, 7 and 10). In
addition, 2/10 pregnancies had preterm births (b37 weeks' gestation).
Of concern, signiﬁcant antepartum hypocalcaemia (corrected
calcium b2.15 mmol/L) occurred in 3/10 pregnancies. Postpartum
hypercalcaemia (corrected calcium N2.65 mmol/L) was documented in
2/10 pregnancies, with a peak serum of 3.01 mmol/L (pregnancy 7) and
4.16mmol/L (pregnancy9) in the setting of lackof adjustment of calcitriol
doses post-partum.4. Discussion
During pregnancy, a term foetus acquires approximately 30 g of cal-
cium, with the majority acquired during the third trimester (Kovacs,
2011). To accommodate this, themother undergoes several adaptations
to calcium handling (Kovacs, 2011; Cooper, 2011; Parkes et al., 2013).
Throughout the ﬁrst and second trimester, parathyroid hormone
(PTH) levels are normal or suppressed, and then gradually increase
during the third trimester.
From the 12th week of pregnancy, the earliest time point for
which data are reported, intestinal calcium absorption doubles. This is
thought to be associated with increased 1,25-dihydroxyvitamin D
levels. Urinary calcium excretion also increases, exceeding the normal
range (N275 mg/24 h) (Kovacs and Kronenberg, 1997). There is evi-
dence demonstrating increased bone resorption from early pregnancy
to mid-pregnancy (estimated by bone markers), in conjunction with
suppressed bone formation which then increases to normal in the
third trimester (Kovacs and Kronenberg, 1997). Serum calcitonin,
parathyroid hormone-related protein (PTHrP), prolactin, placental
lactogen and insulin-like growth factor 1 are other hormones contribut-
ing to calcium homeostasis. When breastfeeding, women typically lose
210 mg of calcium through breast milk each day (Kovacs, 2011). This
is primarily attributed to mammary-derived PTHrP and low oestradiol,







2× miscarriage Presented with pre-epileptic aura
2× miscarriage Suspected IUGR; SGA (3rd centile) Several presentations with
peripheral paraesthesia Postpartum hypercalcaemia (2.61 mmol/L)
3× miscarriage; SGA (10th centile) Postpartum hypercalcaemia (3.01 mmol/L)
Preterm (36/40)
Postpartum hypercalcaemic crisis (4.16 mmol/L)
Preterm (34/40); suspected IUGR; SGA (3rd centile)
m (cCalcium), calcitriol dose, gestational age and complicationswere summarised. Normal
tion; SGA = small for gestational age; IUGR = intrauterine growth restriction.
18 B.L. Hatswell et al. / Bone Reports 3 (2015) 15–19skeleton. Loss of bone density continues during the period of lactation
but is compensated after weaning (More et al., 2001).
PTH is normally responsible for maintaining calcium homeostasis.
Absence of this hormone in conjunction with the increased calcium de-
mands during pregnancy can result in hypocalcaemia if inadequately
supplemented (Kovacs, 2011; Mestman, 1998; Kovacs, 2014). During
lactation, however, PTH is not required for calcium mobilisation, and
supplementation must be reduced to prevent hypercalcaemia.
The most common cause of hypoparathyroidism in the general
population is thyroid surgery, posing a risk of 0.50–6.60%, depending
on the baseline thyroid disorder, thyroid volume, the extent of thyroid
ablation, and experience of the surgeon (Shoback, 2008). Postoperative
hypoparathyroidism is most commonly associated with surgery
for substernal goitre, head or neck malignancies, or Graves' disease
(Bilezikian et al., 2011). The highest incidence of Graves' disease is
between the ages of 40–60 (Tunbridge et al., 1977), whilst the median
age of diagnosis of thyroid cancer is 40–45 (Gimm, 2001). As many
women conceive in younger years, this may explain why hypoparathy-
roidism is rarely encountered during pregnancy. In our study, the most
common causes were idiopathic hypoparathyroidism and congenital
hypoparathyroidism.
Branchial arch disorders (also referred to as pharyngeal or aortic
arch disorders) develop during the 2nd to 6th week of gestation and
are due to abnormal development of the branchial apparatus (Prasad
et al., 2014). DiGeorge syndrome is a 22q11deletion syndrome resulting
in 3rd and 4th branchial pouch anomalies. It is characterised by the
presence of cardiac anomalies, immunological abnormalities, cleft lip
and palate, hypoparathyroidism, learning disabilities, and schizophre-
nia (Botto et al., 2003). Though one of the mothers in our case study
(pregnancy 4, 5, 6) was initially labelled with DiGeorge syndrome, this
was subsequently excluded due to normal karyotype and ﬂuorescent
in situ hybridization as well as absence of cardiac and immune anoma-
lies. She was referred to geneticists for further evaluation and results of
further investigations were not available.
Hypocalcaemia increases uterine irritability, reduces the resting po-
tential, and affects spike frequency of the muscle ﬁbres (Mitchell and
Jüppner, 2010), which may have contributed to the incidence of 2/10
preterm deliveries and history of multiple miscarriages in the two
womenwith congenital hypoparathyroidism. The usual rate of preterm
delivery is 0.80/10 of all pregnancies in Australia (Laws et al., 2006).
SGA is deﬁned as having a birth weight more than 2 standard
deviations below the mean, or less than the 10th percentile for the
gestational age (Dobbins et al., 2013). Given that 3/10 neonates met
the classiﬁcation for SGA, this suggests that there may be an association
of SGA with hypoparathyroidism in pregnancy and warrants further
study.
In our audit, calcium levels throughout pregnancy demonstrated
a peak calcium reading during the 3rd trimester for 6/10 pregnancies.
2/6 of these exceeded the maximum recommended corrected calcium
range (N2.65 mmol/L). Postpartum hypercalcaemia was present in 2
of the pregnancies, pregnancy 7 and 9, and both were associated with
unchanged medication following delivery. Pregnancy 7 reached a peak
of 3.01 mmol/L on day 21, on which day calcitriol dose was noted to
be decreased from 1500 mcg to 1000 mcg. Pregnancy 9 presented in
hypercalcaemic crisis (corrected calcium 4.16 mmol/L) on day 9 post-
partum. She had maintained eucalcaemia throughout pregnancy but
calcitriol doses were not decreased following delivery. This highlights
the importance of closely monitoring serum calcium levels postpartum
and managing accordingly.
During the immediate postpartum period, serum calcium levels in
neonates are decreased in response to decreased PTHrP and maternal
supplementation. Calcium levels then stabilise over the proceeding
24–48 h with stimulation of PTH secretion (Blackburn, 2013). Maternal
calcium disorders may alter calcium homeostasis and parathyroid
function in the newborn if calcium levels are not maintained within
the normal range (Thomas et al., 1999). Infants are at risk ofhyperparathyroidism if their mothers have hypoparathyroidism,
which may be associated with several skeletal deformities and respira-
tory difﬁculties (Hsu and Levine, 2004). Given these complications, it
has been suggested in the literature that neonatal calcium levels are
monitored in the ﬁrst few weeks of life (Wright et al., 1969). Our
study was limited by the retrospective collection of data, with varied
postpartum follow upwith transfer of care out of a tertiary referral cen-
tre to local doctors. Data were also only available on neonatal calcium
levels in three pregnancies and these levels were normal.
Currently there are no best practice guidelines for management of
maternal hypoparathyroidism during pregnancy. Our study highlights
the need to monitor serum calcium levels during pregnancy and in the
postpartum period. We have identiﬁed the varying aetiologies of hypo-
parathyroidism in young women of reproductive age and highlighted
the known association of recurrent miscarriage with this condition.
Whether there is a potential association of SGA with hypoparathyroid-
ism in pregnancy is an important consideration and needs further
evaluation.
In pregnancy, ionised calcium or albumin-corrected serum calcium
ismaintained in the low tomid normal range. The calcitriol dose should
be adjusted based on the ionised calcium or corrected serum calcium
level. Calcitriol has a shorter half-life compared with the older prepara-
tions including high-dose cholecalciferol. Cholecalciferol requires high
levels of 25-hydroxyvitaminDof greater than 250nmol/L: the associated
toxicity of high dose preparations makes calcitriol the preferred medica-
tion. However, studies examining calcitriol in pregnancy are limited.4.1. Conclusion
The requirements for exogenous calcitriol vary during the second
half of pregnancy but are expected to decrease substantially (if not
completely) during lactation. We recommend monitoring calcium
levels every three to four weeks throughout pregnancy, and within
one week post-partum to ensure normocalcaemia in both mother and
baby. During lactation, monitoring should occur every 4 to 6 weeks,
with review during weaning to ensure stability of maternal calcium
levels. Expecting and lactating mothers should be made aware of the
symptoms of both hypercalcaemia and hypocalcaemia and given
instructions to urgently seekmedical care if these symptoms occur.Writ-
ten information given to the patient during pregnancy is recommended
to ensure understanding of the condition, the need for monitoring and
reduction of calcitriol following delivery. Education of medical and
nursing staff about this rare condition in pregnancy is essential to avoid
complications. Coordinated care between endocrinologists and obstetri-
cians is essential to ensure optimal outcomes and the establishment of a
multi-centred database to prospectively study hypoparathyroidism and
pregnancy outcomes is warranted.Author contributions
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